Downregulation Of Bcsg1 May Correlate With Better Outcome Of Neoadjuvant Chemotherapy For Triple-Negative Breast Cancer

The aim of this study was to investigate the correlation between breast cancer-specific gene I (BCSG1) and the effect of neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC). Real-time RT-PCR and immunohistochemistry were used to determine the expression of BCSG1 mRNA and protein levels of 32 TNBC patients before and after NAC. Tumor size was reduced significantly after NAC in all 32 TNBC patients. The expression of BCSG1 was also decreased after NAC at both m RNA and protein levels. There was a negative correlation between BCSG1 levels after NAC and the effect of NAC. BCSG1 may be a potential target for NAC in the treatment of TNBC.